CD Antigen Cancer Therapy Market Size, Trends and Insights By Type of CD Antigen Targeted (CD19, CD20, CD30, CD33, CD38, CD70, Others), By Therapy Type (Monoclonal Antibodies (mAbs), Antibody-Drug Conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cell Therapy, Bi-specific T-cell Engagers (BiTEs), Radioimmunotherapy, Immunotoxins), By Cancer Type (Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Lung Cancer, Prostate Cancer, Others), By End User (Hospitals, Specialty Clinics, Cancer Treatment Centers, Research Institutes), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- Novartis AG
- Roche Holdings AG
- Bristol Myers Squibb Company
- Gilead Sciences Inc.
- Merck & Co. Inc.
- Johnson & Johnson
- Others
Reports Description
As per the current market research conducted by the CMI Team, the global CD Antigen Cancer Therapy Market is expected to record a CAGR of 6.4% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 27,324.6 Million. By 2033, the valuation is anticipated to reach USD 47,756.1 Million.
The CD antigen cancer therapy market encompasses the development and commercialization of therapies targeting specific cell surface proteins, known as CD antigens, implicated in cancer progression. These therapies include monoclonal antibodies, antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bi-specific T-cell engagers (BiTEs).
By selectively targeting cancer cells while sparing healthy tissue, CD antigen therapies offer the potential for improved treatment efficacy and reduced toxicity. With ongoing research into novel CD antigens and innovative therapeutic approaches, the market continues to expand, addressing unmet medical needs and driving advancements in cancer care.
CD Antigen Cancer Therapy Market – Significant Growth Factors
The CD Antigen Cancer Therapy Market presents significant growth opportunities due to several factors:
- Advancements in Immunotherapy: The increasing understanding of immune system interactions with cancer cells has propelled the development of CD antigen cancer therapies. Advancements in immunotherapy, including CAR-T cell therapy and immune checkpoint inhibitors, have driven the demand for CD antigen-targeted treatments.
- Growing Incidence of Cancer: With the rising prevalence of cancer worldwide, there’s a growing demand for effective treatment options. CD antigen cancer therapies offer targeted approaches that can improve treatment outcomes, leading to increased adoption and market growth.
- Technological Innovations: Advances in biotechnology and genetic engineering have facilitated the development of novel CD antigen-targeted therapies, such as antibody-drug conjugates (ADCs) and bispecific antibodies. These technological innovations drive the expansion of the CD antigen cancer therapy market.
- Shift Towards Personalized Medicine: There’s a growing trend towards personalized medicine in oncology, driven by the need for more effective and tailored treatment options. CD antigen therapies can be customized based on individual patient profiles, offering opportunities for precise and targeted cancer treatment.
- Expanding Indications: There is an opportunity to explore new indications and expand the use of CD antigen cancer therapies across various cancer types. By identifying additional CD antigens and their roles in different cancers, companies can develop therapies for unmet medical needs and broaden their market reach.
CD Antigen Cancer Therapy Market – Mergers and Acquisitions
The CD Antigen Cancer Therapy Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the CD Antigen Cancer Therapy Market include:
- In 2021, TUKYSA® (tucatinib) gained approval in the U.S. and other nations for specific HER2+ metastatic breast cancers, in combination with trastuzumab and capecitabine. It marks the third approved therapy and the first wholly owned medicine in this context.
- In 2022, Seagen’s partnership with Pfizer’s Array BioPharma involves the manufacture, development, and sale of Tukysa, a medication for breast and colorectal cancer. This collaboration strengthens Seagen’s position in the oncology market and expands treatment options for cancer patients.
- In 2023, Gilead Sciences, Inc. obtained FDA approval for Trodelvy to treat inoperable locally advanced or metastatic breast cancer in adults. This approval expands treatment options and is expected to improve outcomes for patients with breast cancer, addressing unmet medical needs in the market.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the CD Antigen Cancer Therapy Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| CD Antigen Cancer Therapy Market | Personalized Cancer Medicine Market | Penile Cancer Treatment Market |
| CAGR 6.4% (Approx) | CAGR 8.2% (Approx) | CAGR 7.8% (Approx) |
| USD 47,756.1 Million by 2033 | USD 707.1 Billion by 2033 | USD 12.9 Billion by 2032 |
CD Antigen Cancer Therapy Market – Significant Threats
The CD Antigen Cancer Therapy Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
- Resistance and Relapse: One significant threat is the development of resistance to CD antigen-targeted therapies, leading to treatment failure and disease relapse. Tumor cells can evolve mechanisms to evade therapy, reducing treatment efficacy and limiting long-term patient outcomes.
- Toxicity and Side Effects: Another threat is the potential for toxicity and adverse side effects associated with CD antigen-targeted therapies. While these treatments are designed to selectively target cancer cells, they may also impact healthy tissues expressing the targeted CD antigens, leading to off-target effects and treatment-related complications.
- Competition and Market Saturation: The CD antigen cancer therapy market is highly competitive, with numerous players developing similar therapies targeting overlapping CD antigens. Intense competition can lead to pricing pressures, reduced market share, and challenges in differentiating products, posing a threat to profitability and sustainability.
- Regulatory and Reimbursement Challenges: Regulatory hurdles, including stringent approval processes and evolving safety requirements, present a significant threat to CD antigen cancer therapies. Delays or failures in obtaining regulatory approvals can hinder market entry and limit patient access to innovative treatments. Additionally, challenges in securing reimbursement for novel therapies may impact market adoption and commercial success.
Category-Wise Insights
By Type of CD Antigen Targeted:
- CD19: CD19-targeted therapies, such as CAR-T cell therapy and monoclonal antibodies, are used primarily in the treatment of B-cell malignancies, including leukemia and lymphoma. Trends include the development of novel CAR-T constructs with enhanced persistence and efficacy, and the exploration of combination therapies.
- CD20: CD20-targeted therapies, predominantly monoclonal antibodies like rituximab, are utilized in B-cell lymphomas and leukemias. Trends include the development of next-generation anti-CD20 antibodies with improved efficacy and reduced immunogenicity, as well as combination strategies with chemotherapy and immunomodulators.
- CD30: CD30-targeted therapies, including antibody-drug conjugates (ADCs) like brentuximab vedotin, are employed in Hodgkin lymphoma and other CD30-expressing lymphomas. Trends include the exploration of novel ADC payloads and combination approaches, as well as the investigation of CD30-targeted immunotherapies such as CAR-T cells.
- CD33: CD33-targeted therapies, such as gemtuzumab ozogamicin, are utilized in acute myeloid leukemia (AML). Trends include the development of next-generation CD33-targeted ADCs with improved therapeutic indices and reduced off-target effects, as well as combination strategies with chemotherapy and targeted agents.
- CD38: CD38-targeted therapies, like daratumumab, are primarily used in multiple myeloma. Trends include the expansion of CD38-targeted therapies into other hematologic malignancies and solid tumors, the development of subcutaneous formulations for improved convenience, and combination regimens with immunomodulatory drugs and proteasome inhibitors.
- CD70: CD70-targeted therapies, such as antibody-drug conjugates and CAR-T cell therapies, are under investigation for various malignancies, including renal cell carcinoma and non-Hodgkin lymphoma. Trends include the advancement of CD70-targeted immunotherapies into clinical trials, with a focus on identifying optimal treatment strategies and patient populations.
- Others: This category encompasses CD antigens beyond CD19-CD70, including emerging targets like CD123 and CD44. Trends include the exploration of novel CD antigens as therapeutic targets, the development of innovative antibody constructs and immunotherapies, and the identification of biomarkers predictive of response to CD antigen-targeted therapies.
By Therapy Type
- Monoclonal Antibodies (mAbs): Monoclonal antibodies are proteins designed to target specific CD antigens on cancer cells, triggering immune responses against tumors. Trends include the development of novel mAbs targeting emerging CD antigens, combination therapies with immune checkpoint inhibitors, and advancements in antibody engineering for improved efficacy.
- Antibody-Drug Conjugates (ADCs): ADCs are monoclonal antibodies conjugated to cytotoxic drugs, delivering chemotherapy directly to cancer cells expressing CD antigens. Trends include the development of next-generation ADCs with improved payload delivery, site-specific conjugation technologies, and novel linker designs to enhance tumor targeting and reduce off-target toxicity.
- Chimeric Antigen Receptor (CAR) T-cell Therapy: CAR T-cell therapy involves engineering patients’ T-cells to express synthetic receptors targeting CD antigens, enabling potent anti-tumor immune responses. Trends include the expansion of CAR T-cell therapies beyond haematological malignancies, optimization of CAR designs for improved safety and efficacy, and the development of off-the-shelf CAR T-cell products.
- Bi-specific T-cell Engagers (BiTEs): BiTEs are bi-specific antibodies designed to simultaneously bind CD antigens on cancer cells and T-cells, promoting tumor cell killing. Trends include the development of BiTEs targeting novel CD antigens, combination therapies with checkpoint inhibitors, and advances in BiTE engineering for enhanced potency and reduced immunogenicity.
- Radioimmunotherapy, Immunotoxins: Radioimmunotherapy involves the use of radioisotopes conjugated to monoclonal antibodies to deliver targeted radiation to cancer cells expressing CD antigens. Immunotoxins are fusion proteins combining antibodies with cytotoxic agents, inducing cell death. Trends include the development of novel radioisotopes and toxins for improved tumor targeting and therapeutic efficacy.
By End User
- Hospitals: Hospitals are primary providers of cancer treatment, including CD antigen therapies. Trends include the adoption of comprehensive cancer care programs integrating CD antigen therapies, investment in advanced oncology departments, and collaboration with research institutions for clinical trials.
- Specialty Clinics: Specialty clinics focus on specific cancer types, offering targeted CD antigen therapies alongside supportive care services. Trends include niche specialization, patient-centered approaches, and integration of multidisciplinary care teams for personalized treatment plans.
- Cancer Treatment Centers: Dedicated cancer treatment centers offer a range of CD antigen therapies supported by state-of-the-art facilities and expertise. Trends include an emphasis on evidence-based practices, patient advocacy, and the adoption of innovative technologies for precision oncology.
- Research Institutes: Research institutes drive innovation in CD antigen cancer therapy through preclinical studies and clinical trials. Trends include translational research, biomarker discovery, and collaboration with industry partners for drug development and validation.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 27,324.6 Million |
| Projected Market Size in 2033 | USD 47,756.1 Million |
| Market Size in 2023 | USD 25,681.1 Million |
| CAGR Growth Rate | 6.4% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Type of CD Antigen Targeted, Therapy Type, Cancer Type, End User and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
CD Antigen Cancer Therapy Market – Regional Analysis
The CD Antigen Cancer Therapy Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:
- North America: In North America, trends in the CD antigen cancer therapy market include a strong emphasis on precision medicine and personalized oncology, with robust investments in genomic profiling and targeted therapy development. Additionally, there’s a focus on collaborative research efforts between academia, industry, and government institutions to drive innovation and accelerate drug discovery and development processes.
- Europe: In Europe, trends in the CD antigen cancer therapy market revolve around regulatory harmonization and streamlined approval processes to facilitate timely access to innovative therapies. There’s also a growing focus on cost-effectiveness and value-based healthcare models, prompting the adoption of CD antigen therapies that demonstrate improved clinical outcomes and cost savings over traditional treatments.
- Asia-Pacific: In the Asia-Pacific region, trends in the CD antigen cancer therapy market include increasing investments in healthcare infrastructure and oncology research, particularly in countries like China, Japan, and South Korea. There’s a growing demand for affordable and accessible cancer treatments, driving the adoption of CD antigen therapies as part of comprehensive cancer care programs.
- LAMEA (Latin America, Middle East & Africa): In LAMEA, trends in the CD antigen cancer therapy market are characterized by efforts to address healthcare disparities and improve access to innovative treatments in underserved regions. Governments and healthcare organizations are investing in capacity building, clinical trials infrastructure, and healthcare reforms to expand access to CD antigen therapies and improve cancer outcomes.
Competitive Landscape – CD Antigen Cancer Therapy Market
The CD Antigen Cancer Therapy Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:
- Novartis AG
- Roche Holdings AG
- Bristol Myers Squibb Company
- Gilead Sciences Inc.
- Merck & Co. Inc.
- Johnson & Johnson
- Amgen Inc.
- AbbVie Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- Seattle Genetics Inc.
- Biogen Inc.
- Celgene Corporation
- Genmab A/S
- Immunomedics Inc.
- Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
New players entering the CD antigen cancer therapy market are leveraging innovation and development to establish their presence. Companies like Adaptimmune Therapeutics and Fate Therapeutics are pioneering novel approaches such as engineered T-cell therapies and induced pluripotent stem cell (iPSC)-derived cell therapies.
Dominating the market are key players like Novartis AG, Roche Holdings AG, and Bristol Myers Squibb Company, with extensive R&D investments, established product pipelines, and strategic partnerships. They lead through a combination of clinical success, regulatory approvals, and strong market presence, securing their dominance in the industry.
The CD Antigen Cancer Therapy Market is segmented as follows:
By Type of CD Antigen Targeted
- CD19
- CD20
- CD30
- CD33
- CD38
- CD70
- Others
By Therapy Type
- Monoclonal Antibodies (mAbs)
- Antibody-Drug Conjugates (ADCs)
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Bi-specific T-cell Engagers (BiTEs)
- Radioimmunotherapy
- Immunotoxins
By Cancer Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Others
By End User
- Hospitals
- Specialty Clinics
- Cancer Treatment Centers
- Research Institutes
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global CD Antigen Cancer Therapy Market, (2024 – 2033) (USD Million)
- 2.2 Global CD Antigen Cancer Therapy Market: snapshot
- Chapter 3. Global CD Antigen Cancer Therapy Market – Industry Analysis
- 3.1 CD Antigen Cancer Therapy Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Advancements in Immunotherapy
- 3.2.2 Growing Incidence of Cancer
- 3.2.3 Technological Innovations
- 3.2.4 Shift Towards Personalized Medicine
- 3.2.5 Expanding Indications.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type of CD Antigen Targeted
- 3.7.2 Market Attractiveness Analysis By Therapy Type
- 3.7.3 Market Attractiveness Analysis By Cancer Type
- 3.7.4 Market Attractiveness Analysis By End User
- Chapter 4. Global CD Antigen Cancer Therapy Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global CD Antigen Cancer Therapy Market: Company Market Share, 2023
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global CD Antigen Cancer Therapy Market – Type of CD Antigen Targeted Analysis
- 5.1 Global CD Antigen Cancer Therapy Market Overview: By Type of CD Antigen Targeted
- 5.1.1 Global CD Antigen Cancer Therapy Market Share, By Type of CD Antigen Targeted, 2023 and 2033
- 5.2 CD19
- 5.2.1 Global CD Antigen Cancer Therapy Market by CD19, 2024 – 2033 (USD Million)
- 5.3 CD20
- 5.3.1 Global CD Antigen Cancer Therapy Market by CD20, 2024 – 2033 (USD Million)
- 5.4 CD30
- 5.4.1 Global CD Antigen Cancer Therapy Market by CD30, 2024 – 2033 (USD Million)
- 5.5 CD33
- 5.5.1 Global CD Antigen Cancer Therapy Market by CD33, 2024 – 2033 (USD Million)
- 5.6 CD38
- 5.6.1 Global CD Antigen Cancer Therapy Market by CD38, 2024 – 2033 (USD Million)
- 5.7 CD70
- 5.7.1 Global CD Antigen Cancer Therapy Market by CD70, 2024 – 2033 (USD Million)
- 5.8 Others
- 5.8.1 Global CD Antigen Cancer Therapy Market by Others, 2024 – 2033 (USD Million)
- 5.1 Global CD Antigen Cancer Therapy Market Overview: By Type of CD Antigen Targeted
- Chapter 6. Global CD Antigen Cancer Therapy Market – Therapy Type Analysis
- 6.1 Global CD Antigen Cancer Therapy Market Overview: By Therapy Type
- 6.1.1 Global CD Antigen Cancer Therapy Market Share, By Therapy Type, 2023 and 2033
- 6.2 Monoclonal Antibodies (mAbs)
- 6.2.1 Global CD Antigen Cancer Therapy Market by Monoclonal Antibodies (mAbs), 2024 – 2033 (USD Million)
- 6.3 Antibody-Drug Conjugates (ADCs)
- 6.3.1 Global CD Antigen Cancer Therapy Market by Antibody-Drug Conjugates (ADCs), 2024 – 2033 (USD Million)
- 6.4 Chimeric Antigen Receptor (CAR) T-cell Therapy
- 6.4.1 Global CD Antigen Cancer Therapy Market by Chimeric Antigen Receptor (CAR) T-cell Therapy, 2024 – 2033 (USD Million)
- 6.5 Bi-specific T-cell Engagers (BiTEs)
- 6.5.1 Global CD Antigen Cancer Therapy Market by Bi-specific T-cell Engagers (BiTEs), 2024 – 2033 (USD Million)
- 6.6 Radioimmunotherapy
- 6.6.1 Global CD Antigen Cancer Therapy Market by Radioimmunotherapy, 2024 – 2033 (USD Million)
- 6.7 Immunotoxins
- 6.7.1 Global CD Antigen Cancer Therapy Market by Immunotoxins, 2024 – 2033 (USD Million)
- 6.1 Global CD Antigen Cancer Therapy Market Overview: By Therapy Type
- Chapter 7. Global CD Antigen Cancer Therapy Market – Cancer Type Analysis
- 7.1 Global CD Antigen Cancer Therapy Market Overview: By Cancer Type
- 7.1.1 Global CD Antigen Cancer Therapy Market Share, By Cancer Type, 2023 and 2033
- 7.2 Leukemia
- 7.2.1 Global CD Antigen Cancer Therapy Market by Leukemia, 2024 – 2033 (USD Million)
- 7.3 Lymphoma
- 7.3.1 Global CD Antigen Cancer Therapy Market by Lymphoma, 2024 – 2033 (USD Million)
- 7.4 Multiple Myeloma
- 7.4.1 Global CD Antigen Cancer Therapy Market by Multiple Myeloma, 2024 – 2033 (USD Million)
- 7.5 Breast Cancer
- 7.5.1 Global CD Antigen Cancer Therapy Market by Breast Cancer, 2024 – 2033 (USD Million)
- 7.6 Lung Cancer
- 7.6.1 Global CD Antigen Cancer Therapy Market by Lung Cancer, 2024 – 2033 (USD Million)
- 7.7 Prostate Cancer
- 7.7.1 Global CD Antigen Cancer Therapy Market by Prostate Cancer, 2024 – 2033 (USD Million)
- 7.8 Others
- 7.8.1 Global CD Antigen Cancer Therapy Market by Others, 2024 – 2033 (USD Million)
- 7.1 Global CD Antigen Cancer Therapy Market Overview: By Cancer Type
- Chapter 8. Global CD Antigen Cancer Therapy Market – End User Analysis
- 8.1 Global CD Antigen Cancer Therapy Market Overview: By End User
- 8.1.1 Global CD Antigen Cancer Therapy Market Share, By End User, 2023 and 2033
- 8.2 Hospitals
- 8.2.1 Global CD Antigen Cancer Therapy Market by Hospitals, 2024 – 2033 (USD Million)
- 8.3 Specialty Clinics
- 8.3.1 Global CD Antigen Cancer Therapy Market by Specialty Clinics, 2024 – 2033 (USD Million)
- 8.4 Cancer Treatment Centers
- 8.4.1 Global CD Antigen Cancer Therapy Market by Cancer Treatment Centers, 2024 – 2033 (USD Million)
- 8.5 Research Institutes
- 8.5.1 Global CD Antigen Cancer Therapy Market by Research Institutes, 2024 – 2033 (USD Million)
- 8.1 Global CD Antigen Cancer Therapy Market Overview: By End User
- Chapter 9. CD Antigen Cancer Therapy Market – Regional Analysis
- 9.1 Global CD Antigen Cancer Therapy Market Regional Overview
- 9.2 Global CD Antigen Cancer Therapy Market Share, by Region, 2023 & 2033 (USD Million)
- 9.3. North America
- 9.3.1 North America CD Antigen Cancer Therapy Market, 2024 – 2033 (USD Million)
- 9.3.1.1 North America CD Antigen Cancer Therapy Market, by Country, 2024 – 2033 (USD Million)
- 9.3.1 North America CD Antigen Cancer Therapy Market, 2024 – 2033 (USD Million)
- 9.4 North America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted, 2024 – 2033
- 9.4.1 North America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted, 2024 – 2033 (USD Million)
- 9.5 North America CD Antigen Cancer Therapy Market, by Therapy Type, 2024 – 2033
- 9.5.1 North America CD Antigen Cancer Therapy Market, by Therapy Type, 2024 – 2033 (USD Million)
- 9.6 North America CD Antigen Cancer Therapy Market, by Cancer Type, 2024 – 2033
- 9.6.1 North America CD Antigen Cancer Therapy Market, by Cancer Type, 2024 – 2033 (USD Million)
- 9.7 North America CD Antigen Cancer Therapy Market, by End User, 2024 – 2033
- 9.7.1 North America CD Antigen Cancer Therapy Market, by End User, 2024 – 2033 (USD Million)
- 9.8. Europe
- 9.8.1 Europe CD Antigen Cancer Therapy Market, 2024 – 2033 (USD Million)
- 9.8.1.1 Europe CD Antigen Cancer Therapy Market, by Country, 2024 – 2033 (USD Million)
- 9.8.1 Europe CD Antigen Cancer Therapy Market, 2024 – 2033 (USD Million)
- 9.9 Europe CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted, 2024 – 2033
- 9.9.1 Europe CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted, 2024 – 2033 (USD Million)
- 9.10 Europe CD Antigen Cancer Therapy Market, by Therapy Type, 2024 – 2033
- 9.10.1 Europe CD Antigen Cancer Therapy Market, by Therapy Type, 2024 – 2033 (USD Million)
- 9.11 Europe CD Antigen Cancer Therapy Market, by Cancer Type, 2024 – 2033
- 9.11.1 Europe CD Antigen Cancer Therapy Market, by Cancer Type, 2024 – 2033 (USD Million)
- 9.12 Europe CD Antigen Cancer Therapy Market, by End User, 2024 – 2033
- 9.12.1 Europe CD Antigen Cancer Therapy Market, by End User, 2024 – 2033 (USD Million)
- 9.13. Asia Pacific
- 9.13.1 Asia Pacific CD Antigen Cancer Therapy Market, 2024 – 2033 (USD Million)
- 9.13.1.1 Asia Pacific CD Antigen Cancer Therapy Market, by Country, 2024 – 2033 (USD Million)
- 9.13.1 Asia Pacific CD Antigen Cancer Therapy Market, 2024 – 2033 (USD Million)
- 9.14 Asia Pacific CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted, 2024 – 2033
- 9.14.1 Asia Pacific CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted, 2024 – 2033 (USD Million)
- 9.15 Asia Pacific CD Antigen Cancer Therapy Market, by Therapy Type, 2024 – 2033
- 9.15.1 Asia Pacific CD Antigen Cancer Therapy Market, by Therapy Type, 2024 – 2033 (USD Million)
- 9.16 Asia Pacific CD Antigen Cancer Therapy Market, by Cancer Type, 2024 – 2033
- 9.16.1 Asia Pacific CD Antigen Cancer Therapy Market, by Cancer Type, 2024 – 2033 (USD Million)
- 9.17 Asia Pacific CD Antigen Cancer Therapy Market, by End User, 2024 – 2033
- 9.17.1 Asia Pacific CD Antigen Cancer Therapy Market, by End User, 2024 – 2033 (USD Million)
- 9.18. Latin America
- 9.18.1 Latin America CD Antigen Cancer Therapy Market, 2024 – 2033 (USD Million)
- 9.18.1.1 Latin America CD Antigen Cancer Therapy Market, by Country, 2024 – 2033 (USD Million)
- 9.18.1 Latin America CD Antigen Cancer Therapy Market, 2024 – 2033 (USD Million)
- 9.19 Latin America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted, 2024 – 2033
- 9.19.1 Latin America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted, 2024 – 2033 (USD Million)
- 9.20 Latin America CD Antigen Cancer Therapy Market, by Therapy Type, 2024 – 2033
- 9.20.1 Latin America CD Antigen Cancer Therapy Market, by Therapy Type, 2024 – 2033 (USD Million)
- 9.21 Latin America CD Antigen Cancer Therapy Market, by Cancer Type, 2024 – 2033
- 9.21.1 Latin America CD Antigen Cancer Therapy Market, by Cancer Type, 2024 – 2033 (USD Million)
- 9.22 Latin America CD Antigen Cancer Therapy Market, by End User, 2024 – 2033
- 9.22.1 Latin America CD Antigen Cancer Therapy Market, by End User, 2024 – 2033 (USD Million)
- 9.23. The Middle-East and Africa
- 9.23.1 The Middle-East and Africa CD Antigen Cancer Therapy Market, 2024 – 2033 (USD Million)
- 9.23.1.1 The Middle-East and Africa CD Antigen Cancer Therapy Market, by Country, 2024 – 2033 (USD Million)
- 9.23.1 The Middle-East and Africa CD Antigen Cancer Therapy Market, 2024 – 2033 (USD Million)
- 9.24 The Middle-East and Africa CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted, 2024 – 2033
- 9.24.1 The Middle-East and Africa CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted, 2024 – 2033 (USD Million)
- 9.25 The Middle-East and Africa CD Antigen Cancer Therapy Market, by Therapy Type, 2024 – 2033
- 9.25.1 The Middle-East and Africa CD Antigen Cancer Therapy Market, by Therapy Type, 2024 – 2033 (USD Million)
- 9.26 The Middle-East and Africa CD Antigen Cancer Therapy Market, by Cancer Type, 2024 – 2033
- 9.26.1 The Middle-East and Africa CD Antigen Cancer Therapy Market, by Cancer Type, 2024 – 2033 (USD Million)
- 9.27 The Middle-East and Africa CD Antigen Cancer Therapy Market, by End User, 2024 – 2033
- 9.27.1 The Middle-East and Africa CD Antigen Cancer Therapy Market, by End User, 2024 – 2033 (USD Million)
- Chapter 10. Company Profiles
- 10.1 Novartis AG
- 10.1.1 Overview
- 10.1.2 Financials
- 10.1.3 Product Portfolio
- 10.1.4 Business Strategy
- 10.1.5 Recent Developments
- 10.2 Roche Holdings AG
- 10.2.1 Overview
- 10.2.2 Financials
- 10.2.3 Product Portfolio
- 10.2.4 Business Strategy
- 10.2.5 Recent Developments
- 10.3 Bristol Myers Squibb Company
- 10.3.1 Overview
- 10.3.2 Financials
- 10.3.3 Product Portfolio
- 10.3.4 Business Strategy
- 10.3.5 Recent Developments
- 10.4 Gilead Sciences Inc.
- 10.4.1 Overview
- 10.4.2 Financials
- 10.4.3 Product Portfolio
- 10.4.4 Business Strategy
- 10.4.5 Recent Developments
- 10.5 Merck & Co. Inc.
- 10.5.1 Overview
- 10.5.2 Financials
- 10.5.3 Product Portfolio
- 10.5.4 Business Strategy
- 10.5.5 Recent Developments
- 10.6 Johnson & Johnson
- 10.6.1 Overview
- 10.6.2 Financials
- 10.6.3 Product Portfolio
- 10.6.4 Business Strategy
- 10.6.5 Recent Developments
- 10.7 Amgen Inc.
- 10.7.1 Overview
- 10.7.2 Financials
- 10.7.3 Product Portfolio
- 10.7.4 Business Strategy
- 10.7.5 Recent Developments
- 10.8 AbbVie Inc.
- 10.8.1 Overview
- 10.8.2 Financials
- 10.8.3 Product Portfolio
- 10.8.4 Business Strategy
- 10.8.5 Recent Developments
- 10.9 AstraZeneca PLC
- 10.9.1 Overview
- 10.9.2 Financials
- 10.9.3 Product Portfolio
- 10.9.4 Business Strategy
- 10.9.5 Recent Developments
- 10.10 Takeda Pharmaceutical Company Limited
- 10.10.1 Overview
- 10.10.2 Financials
- 10.10.3 Product Portfolio
- 10.10.4 Business Strategy
- 10.10.5 Recent Developments
- 10.11 Seattle Genetics Inc.
- 10.11.1 Overview
- 10.11.2 Financials
- 10.11.3 Product Portfolio
- 10.11.4 Business Strategy
- 10.11.5 Recent Developments
- 10.12 Biogen Inc.
- 10.12.1 Overview
- 10.12.2 Financials
- 10.12.3 Product Portfolio
- 10.12.4 Business Strategy
- 10.12.5 Recent Developments
- 10.13 Celgene Corporation
- 10.13.1 Overview
- 10.13.2 Financials
- 10.13.3 Product Portfolio
- 10.13.4 Business Strategy
- 10.13.5 Recent Developments
- 10.14 Genmab A/S
- 10.14.1 Overview
- 10.14.2 Financials
- 10.14.3 Product Portfolio
- 10.14.4 Business Strategy
- 10.14.5 Recent Developments
- 10.15 Immunomedics Inc.
- 10.15.1 Overview
- 10.15.2 Financials
- 10.15.3 Product Portfolio
- 10.15.4 Business Strategy
- 10.15.5 Recent Developments
- 10.16 Others.
- 10.16.1 Overview
- 10.16.2 Financials
- 10.16.3 Product Portfolio
- 10.16.4 Business Strategy
- 10.16.5 Recent Developments
- 10.1 Novartis AG
List Of Figures
Figures No 1 to 42
List Of Tables
Tables No 1 to 102
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2033
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
FAQs
The key factors driving the Market are Advancements in Immunotherapy, Growing Incidence of Cancer, Technological Innovations, Shift Towards Personalized Medicine, Expanding Indications.
The “Monoclonal Antibodies (mAbs)” category dominated the market in 2023.
The key players in the market are Novartis AG, Roche Holdings AG, Bristol Myers Squibb Company, Gilead Sciences Inc., Merck & Co. Inc., Johnson & Johnson, Amgen Inc., AbbVie Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Seattle Genetics Inc., Biogen Inc., Celgene Corporation , Genmab A/S, Immunomedics Inc., Others.
“Europe” had the largest share in the CD Antigen Cancer Therapy Market.
The global market is projected to grow at a CAGR of 6.4% during the forecast period, 2024-2033.
The CD Antigen Cancer Therapy Market size was valued at USD 27,324.6 Million in 2024.
PURCHASE OPTIONS
What You Get :
- PDF Report Format.
- Can be accessible by 1 single user.
- Free 25% or 40 hours of customisation.
- Free post-sale service assistance.
- 15% discount on your next purchase.
- Dedicated account Associate .
- Permission to print the report.
- Service guarantee available.
- PDF and Excel Datasheet Formats.
- Can be accessible upto 2 to 5 users.
- Free 35% or 60 hours of customisation.
- Free post-sale service assistance.
- 25% discount on your next purchase.
- Service guarantee available.
- Personalised market brief by author.
- Permission to print the report.
- Report in your Language.
- PDF, Excel and Power Point.
- Can be accessible by unlimited users.
- Free 40% or 80 hours of customisation.
- Free post-sale service assistance.
- 30% discount on your next purchase.
- Permission to print the report.
- Dedicated account manager.
- Service guarantee available.
- Report in your Language.
- Excel Datasheet Format.
- Customized access as per user request.
- Upgradable to other licenses.
- 15% discount on your next purchase.
- Free 20% or 10 hours of customisation.
- PDF, Excel, Power Point and Power BI.
- Every Year Free Update ( Apr – Apr)
- Personalized market brief by author
- Can be accessible by unlimited users.
- Free 50% or 90 hours of customization.
- Up to 50 Company Profiles
- Free post-sale service assistance with guarantee
- 40% discount on your next purchase.
- Permission to print the report.
- Dedicated account team.
- Service guarantee available.
- Report in your Language.